Aurora Cannabis pivots to global medical markets as consumer sales fade

Despite the dip in total revenue, the Edmonton-based company saw a 17% increase in international medical cannabis sales, largely fueled by rising demand in Germany. CEO Miguel Martin pointed to the company’s genetics program and EU-GMP manufacturing capacity as central pillars for its international strategy. Aurora finalized its acquisition of Safari Flower Company in April 2026, gaining a 59,000-square-foot facility to bolster high-margin supply chains and reduce reliance on third-party providers.

Financial performance reflects a period of transition. The company posted a net loss of $4.0 million from continuing operations, an improvement from the $10.2 million loss recorded in the same period last year. Adjusted EBITDA fell to $3.4 million, down from $10.8 million, primarily due to compressed margins in the Canadian medical sector following a 30% reduction in federal reimbursement rates. Aurora maintains a debt-free balance sheet with $149.1 million in cash and short-term investments, and management expects both revenue and adjusted EBITDA to rise sequentially in the second quarter.